Publication Details
Long-term survivors of glioblastoma: a closer look
Gately L, McLachlan S, Philip J, Ruben J, Dowling A
(2017), J Neurooncol, 136(1), 155-62
DOI: 10.1007/s11060-017-2635-1
The effects of gold nanoparticles concentrations and beam quality/LET on dose enhancement when irradiated with X-rays and protons using alanine/EPR dosimetry
Smith CL, Best SP, Gagliardi F, Tominaga T, Geso M
(2017), Radiat Meas, 106, 352-6
DOI: 10.1016/j.radmeas.2017.01.019
A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate 192 Ir brachytherapy
Ma Y, Vijande J, Ballester F, Tedgren ?C, Granero D, Haworth A, Mourtada F, Fonseca GP, Zourari K, Papagiannis P, Rivard MJ, Siebert FA, Sloboda RS, Smith R, Chamberland MJP, Thomson RM, Verhaegen F, Beaulieu L
(2017), Med Phys, 44(11), 5961-76
DOI: 10.1002/mp.12459
A randomized controlled trial of an additional funding intervention to improve clinical trial enrollment
Parker C, Snyder R, Jefford M, Dilts D, Wolfe R, Millar J
(2017), J Natl Compr Canc Netw, 15(9), 1104-10
DOI: 10.6004/jnccn.2017.0150
Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer
Ong WL, Foroudi F, Evans S, Millar JL
(2017), BJU Int, 120(Suppl 3), 35-42
DOI: 10.1111/bju.13969
3D catheter reconstruction in HDR prostate brachytherapy for pre-treatment verification using a flat panel detector
Smith RL, Haworth A, Panettieri V, Millar JL, Franich RD
(2017), Phys Med, 39, 121-31
DOI: 10.1016/j.ejmp.2017.06.008
Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes
Evans SM, Millar JL, Moore CM, Lewis JD, Huland H, Sampurno F, Connor SE, Villanti P, Litwin MS
(2017), BMJ Open, 7(11), e017006
DOI: 10.1136/bmjopen-2017-017006
Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer
Woodford K, Panettieri V, Tran Le T, Senthi S
(2017), Clin Trans Radiat Oncol, 6, 21-4
DOI: 10.1016/j.ctro.2017.08.001
Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial
Owen PJ, Daly RM, Livingston PM, Mundell NL, Via JD, Millar JL, Fraser SF
(2017), Trials, 18, 451
DOI: 10.1186/s13063-017-2185-z
Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia
Kirkman M, Young K, Evans S, Millar JL, Fisher J, Mazza D, Ruseckaite R
(2017), BMC Cancer, 17, 704
DOI: 10.1186/s12885-017-3699-1
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Duschesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, D'Este C, Frydenberg M, Loblaw A, Malone S, Millar J, Tai KH, Turner S
(2017), Lancet Oncol, 18(9), 1192-1201
DOI: 10.1016/S1470-2045(17)30426-6
The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers
Oberoi D, White VM, Seymour JF, Miles Prince H, Harrison S, Jefford M, Winship I, Hill D, Bolton D, Kay A, Millar J, Doo NW, Giles G
(2017), Support Care Cancer, 25(11), 3447-56
DOI: 10.1007/s00520-017-3766-9
Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control study
Papa NP, MacInnis RJ, Jayasekara H, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG
(2017), Prostate Cancer Prostatic Dis, 20(3), 305-10
DOI: 10.1038/pcan.2017.12
Ejaculatory frequency and the risk of aggressive prostate cancer: findings from a case-control study
Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG
(2017), Urol Oncol, 35(8), 530e7-13
DOI: 10.1016/j.urolonc.2017.03.007
Population-based study of grade progression in patients who harboured Gleason 3 + 3
Sampurno F, Earnest A, Millar J, Frydenberg M, Murphy D, Delprado W, Evans S
(2017), World J Urol, 35(11), 1689-99
DOI: 10.1007/s00345-017-2047-z
Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study
White V, Marco DJT, Bolton D, Davis ID, Jefford M, Hill D, Prince HM, Millar JL, Winship IM, Coory M, Giles GG
(2017), BJU Int, 120(Suppl 3), 6-14
DOI: 10.1111/bju.13889
High dose rate brachytherapy source measurements intercomparison
Poder J, Smith RL, Shelton N, Whitaker M, Butler D, Haworth A
(2017), Australas Phys Eng Sci Med, 40(2), 377-83
DOI: 10.1007/s13246-017-0542-6
Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy
Beckman K, O'Callaghan M, Vincent A, Roder D, Millar J, Evans S, McNeil J, Moretti K
(2017), ANZ J Surg, 88(3), E183-8
DOI: 10.1111/ans.13954
An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review
Raymond E, O'Callaghan ME, Campbell J, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J
(2017), Radiat Oncol, 12, 56
DOI: 10.1186/s13014-017-0786-z
The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period
Oberoi D, White V, Seymour J, Prince HM, Harrison S, Jefford M, Winship I, Hill D, Bolton D, Kay A, Millar J
(2017), J Cancer Surviv, 11(3), 329-38
DOI: 10.1007/s11764-016-0591-y
